Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) plays a major role in breast cancer therapeutics acting through preventing the cell cycle from G1 to the S phase. Recently, Endocrine therapy combined with CDK4/6i represented a major milestone in hormone receptor (HR)-positive and human epidermal...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lu, Shen, Xiabo, He, Libin, Wu, Jiayi, Liu, Yiyuan, Wang, Xiaojia, Shao, Xiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848408/
https://www.ncbi.nlm.nih.gov/pubmed/35282060
http://dx.doi.org/10.21037/atm-22-52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848408/
https://www.ncbi.nlm.nih.gov/pubmed/35282060
http://dx.doi.org/10.21037/atm-22-52

Ejemplares similares